Fostamatinib for the treatment of chronic immune thrombocytopenia-Reference-Cited by-同舟云学术

Fostamatinib for the treatment of chronic immune thrombocytopenia

Published:2019-05-09 Issue:19 Volume:133 Page:2027-2030
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Connell Nathan T.¹²^ORCID,Berliner Nancy¹²^ORCID

Affiliation:

1. Hematology Division, Brigham and Women’s Hospital, Boston, MA; and

2. Harvard Medical School, Boston, MA

Abstract

Abstract Fostamatinib is a spleen tyrosine kinase inhibitor recently approved for the treatment of chronic immune thrombocytopenia (ITP) in patients without adequate response to at least 1 prior line of therapy. This article reviews fostmatinib’s mechanism of action and its clinical safety and efficacy in 2 industry-sponsored multicenter phase 3 randomized controlled trials in North America, Australia, and Europe (FIT1 and FIT2). Cost comparisons are discussed as well as the role of fostamatinib in relation to other options for chronic ITP.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/133/19/2027/1553337/blood852491.pdf

Reference29 articles.

1. Primary immune thrombocytopenia: understanding pathogenesis is the key to better treatments;Chong;J Thromb Haemost,2009

2. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters;Toltl;Br J Haematol,2011

3. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group;Rodeghiero;Blood,2009

4. How I treat refractory immune thrombocytopenia;Cuker;Blood,2016

5. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up;Kristinsson;Haematologica,2014

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pathological study on the efficacy of Syk inhibitors in a Candida albicans-induced aortic root vasculitis murine model;Cardiovascular Pathology;2024-09

2. Novel treatments for immune thrombocytopenia: targeting platelet autoantibodies;Expert Review of Hematology;2024-08-06

3. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study;The Lancet Haematology;2024-08

4. The Syk Inhibitor Entospletinib Abolishes Dermal–Epidermal Separation in a Fully Human Ex Vivo Model of Bullous Pemphigoid;Journal of Investigative Dermatology;2024-08

5. Development of SYK NanoBRET cellular target engagement assays for gain–of–function variants;Frontiers in Chemical Biology;2024-07-29